Syngene International Expands Capabilities
Syngene International, a global contract research, development and manufacturing organization (CRDMO), announces plans to add a GMP bioconjugation suite.
This new capability will enable Syngene to offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing.
The bioconjugation suite will be located at Syngene's commercial biologics facility in Bengaluru, complementing its existing services for commercial payload, linker, and monoclonal antibodies.
Syngene will be among a handful of CDMOs with full-service capabilities for ADCs.
Author's summary: Syngene International expands ADC capabilities.